PT1815850E - Formulação de libertação controlada de ácido divalpróico e seus derivados - Google Patents

Formulação de libertação controlada de ácido divalpróico e seus derivados Download PDF

Info

Publication number
PT1815850E
PT1815850E PT06250124T PT06250124T PT1815850E PT 1815850 E PT1815850 E PT 1815850E PT 06250124 T PT06250124 T PT 06250124T PT 06250124 T PT06250124 T PT 06250124T PT 1815850 E PT1815850 E PT 1815850E
Authority
PT
Portugal
Prior art keywords
controlled release
derivatives
release formulation
divalproic
acid
Prior art date
Application number
PT06250124T
Other languages
English (en)
Inventor
Nava Shterman
Limor Ari-Pardo
Rina Zilberman
Yonit Triger-Messer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PT1815850E publication Critical patent/PT1815850E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
PT06250124T 2006-01-11 2006-01-11 Formulação de libertação controlada de ácido divalpróico e seus derivados PT1815850E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06250124A EP1815850B1 (en) 2006-01-11 2006-01-11 Controlled release formulation of divalproic acid and its derivatives

Publications (1)

Publication Number Publication Date
PT1815850E true PT1815850E (pt) 2009-01-06

Family

ID=36250729

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06250124T PT1815850E (pt) 2006-01-11 2006-01-11 Formulação de libertação controlada de ácido divalpróico e seus derivados

Country Status (7)

Country Link
EP (1) EP1815850B1 (pt)
AT (1) ATE415151T1 (pt)
DE (1) DE602006003848D1 (pt)
DK (1) DK1815850T3 (pt)
ES (1) ES2317450T3 (pt)
PL (1) PL1815850T3 (pt)
PT (1) PT1815850E (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2017175013A1 (en) * 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US5185159A (en) 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
ES2026198T3 (es) * 1987-07-22 1992-04-16 Farvalsa Ag Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5169642A (en) 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
ES2143481T3 (es) 1992-05-29 2000-05-16 Nikken Chemicals Co Ltd Comprimido de valproato de sodio de liberacion lenta.
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität

Also Published As

Publication number Publication date
EP1815850B1 (en) 2008-11-26
EP1815850A1 (en) 2007-08-08
PL1815850T3 (pl) 2009-05-29
DK1815850T3 (da) 2009-03-16
ATE415151T1 (de) 2008-12-15
ES2317450T3 (es) 2009-04-16
DE602006003848D1 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
HK1073996A1 (en) Use of adapalene for the treatment of dermatological disorders
GB0514463D0 (en) Use of pinolenic acid
MX2011012122A (es) Derivados de tiofeno.
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
UA105229C2 (uk) Фармацевтичний склад
WO2007014124A3 (en) High drug load formulations and dosage forms
PL2151241T3 (pl) Trwały stały preparat zawierający pochodną 4,5-epoksymorfinanową
MX2007000201A (es) Acidos grados de cadena media aplicables como agentes antimicrobianos.
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
ZA201003380B (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof
EP1968606A4 (en) PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
PL1815850T3 (pl) Preparat kwasu diwalproinowego i jego pochodnych do kontrolowanego uwalniania
UA102547C2 (uk) Тверда фармацевтична композиція
WO2008120765A1 (ja) 鎮痛用組成物
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
TW200640472A (en) Solid pharmaceutical composition comprising telithromycin
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
WO2009008004A3 (en) Sustained release formulations of divalproex sodium
MX2012001298A (es) Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano.
WO2008014888A3 (de) Imino-imidazo-pyridinderivate mit antithrombotischer aktivität
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.